Stockreport

Shire Receives European Approval for TAKHZYRO™ (lanadelumab) subcutaneous injection, for the Preventive Treatment of Hereditary Angioedema

SHIRE  (SHPG) 
Last shire earnings: 11/1 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: investors.shire.com
PDF Intended for Global Audience Shire Receives European Approval for TAKHZYRO™ (lanadelumab) subcutaneous injection, for the Preventive Treatment of Hereditary Angioede [Read more]